Thomas B. Hakes

4.2k total citations · 1 hit paper
78 papers, 3.2k citations indexed

About

Thomas B. Hakes is a scholar working on Oncology, Reproductive Medicine and Surgery. According to data from OpenAlex, Thomas B. Hakes has authored 78 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 37 papers in Reproductive Medicine and 34 papers in Surgery. Recurrent topics in Thomas B. Hakes's work include Ovarian cancer diagnosis and treatment (37 papers), Intraperitoneal and Appendiceal Malignancies (21 papers) and Cancer Treatment and Pharmacology (20 papers). Thomas B. Hakes is often cited by papers focused on Ovarian cancer diagnosis and treatment (37 papers), Intraperitoneal and Appendiceal Malignancies (21 papers) and Cancer Treatment and Pharmacology (20 papers). Thomas B. Hakes collaborates with scholars based in United States, Germany and South Korea. Thomas B. Hakes's co-authors include Stephen C. Rubin, John L. Lewis, Bonnie Reichman, Maurie Markman, William J. Hoskins, Lois Almadrones, Wanda K. Jones, Robert Rothman, John P. Curtin and Walter B. Jones and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Consulting and Clinical Psychology.

In The Last Decade

Thomas B. Hakes

76 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.

1991 647 citations Maurie Markman, Robert Rothman et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Thomas B. Hakes

Since Specialization

Citations

This map shows the geographic impact of Thomas B. Hakes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas B. Hakes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas B. Hakes more than expected).

Fields of papers citing papers by Thomas B. Hakes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas B. Hakes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas B. Hakes. The network helps show where Thomas B. Hakes may publish in the future.

Co-authorship network of co-authors of Thomas B. Hakes

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas B. Hakes. A scholar is included among the top collaborators of Thomas B. Hakes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas B. Hakes. Thomas B. Hakes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial. 1994 ·PubMed ·D. Fennelly, Carolyn Wasserheit, Juliane Schneider, Thomas B. Hakes, Lillian Reich, John P. Curtin, Tzy‐Jyun Yao, Maurie Markman, Larry Norton, John Crown	13
2	The Use of Recombinant Human Erythropoietin to Prevent Carboplatin-Induced Anemia 1993 ·Gynecologic Oncology ·Maurie Markman, Bonnie Reichman, Thomas B. Hakes, Stephen C. Rubin, Walter B. Jones, John L. Lewis, Richard R. Barakat, John P. Curtin, Lois Almadrones, William J. Hoskins	29
3	Taxol and Recombinant Human Granulocyte Colony‐Stimulating Factor, an Active Regimen as Initial Therapy for Metastatic Breast Cancer 1993 ·Annals of the New York Academy of Sciences ·Bonnie Reichman, Andrew D. Seidman, John Crown, Robert T. Heelan, T. J. Yao, Thomas B. Hakes, David Lebwohl, Theresa Gilewski, Antonella Surbone, Violante E. Currie, Clifford A. Hudis, (unknown), (unknown), (unknown), Renzo Canetta, Jason S. Fisherman, Susan G. Arbuck, Larry Norton	2
4	Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer. 1992 ·Journal of Clinical Oncology ·Maurie Markman, Bonnie Reichman, Thomas B. Hakes, John L. Lewis, Wanda K. Jones, Stephen C. Rubin, R. Barakat, John P. Curtin, Lois Almadrones, William J. Hoskins	63
5	Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer 1992 ·Gynecologic Oncology ·Maurie Markman, Bonnie Reichman, Thomas B. Hakes, Stephen C. Rubin, Walter B. Jones, John L. Lewis, Richard R. Barakat, John P. Curtin, Lois Almadrones, William J. Hoskins	10
6	Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. 1992 ·Journal of Clinical Oncology ·M Markman, Thomas B. Hakes, Bonnie Reichman, John L. Lewis, Stephen C. Rubin, Wanda K. Jones, Lois Almadrones, (unknown), William J. Hoskins	108
7	Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma 1992 ·Gynecologic Oncology ·Thomas B. Hakes, (unknown), W.J. Hoskins, Walter B. Jones, M Markman, Stephen C. Rubin, (unknown), Lois Almadrones, John L. Lewis	120
8	Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapy 1992 ·Journal of Cancer Research and Clinical Oncology ·Maurie Markman, Bonnie Reichman, Thomas B. Hakes, John P. Curtin, Richard R. Barakat, Stephen C. Rubin, Walter B. Jones, John L. Lewis, Lois Almadrones, William J. Hoskins	1
9	Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. breakdown → 1991 ·Journal of Clinical Oncology ·Maurie Markman, Robert Rothman, Thomas B. Hakes, Bonnie Reichman, William J. Hoskins, Stephen C. Rubin, Wanda K. Jones, Lois Almadrones, John L. Lewis	647
10	Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate 1991 ·Journal of Cancer Research and Clinical Oncology ·Maurie Markman, (unknown), Nicholas Iannotti, Mark G. Kris, Thomas B. Hakes, Dean F. Bajorin, George J. Bosl, Bonnie Reichman, Ephraim S. Casper, Gordon B. Magill, Amy Budnick	32
11	Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. 1991 ·Journal of Clinical Oncology ·Maurie Markman, Bonnie Reichman, Thomas B. Hakes, Wanda K. Jones, John L. Lewis, Stephen C. Rubin, Lois Almadrones, William J. Hoskins	143
12	Interferon-alpha and gamma mediated gene responses in a human breast carcinoma cell line 1991 ·Breast Cancer Research and Treatment ·Raj K. Tiwari, George Y. Wong, Bani Mukhopadhyay, Nitin Telang, (unknown), Thomas B. Hakes, Michael P. Osborne	8
13	Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy 1991 ·Gynecologic Oncology ·Bonnie Reichman, Maurie Markman, Thomas B. Hakes, (unknown), Stephen C. Rubin, Alexandra M. E. Jones, Lois Almadrones, John L. Lewis, William J. Hoskins	13
14	Expression of P-glycoprotein in epithelial ovarian cancer: Evaluation as a marker of multidrug resistance 1990 ·American Journal of Obstetrics and Gynecology ·Stephen C. Rubin, Connie L. Finstad, W.J. Hoskins, Patricia E. Saigo, Diane Provencher, Mark G. Federici, Thomas B. Hakes, Maurie Markman, Bonnie Reichman, Kenneth O. Lloyd, John L. Lewis	31
15	Aggressive chemosurgical debulking in patients with advanced ovarian cancer 1990 ·Gynecologic Oncology ·(unknown), Stephen C. Rubin, William J. Hoskins, Walter B. Jones, Thomas B. Hakes, Maurie Markman, Bonnie Reichman, Lois Almadrones, John L. Lewis	26
16	Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer 1989 ·American Journal of Obstetrics and Gynecology ·Stephen C. Rubin, William J. Hoskins, Thomas B. Hakes, M Markman, Bonnie Reichman, Douglas Chapman, J. L. Lewis	76
17	Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. 1989 ·Journal of Clinical Oncology ·Bonnie Reichman, Maurie Markman, Thomas B. Hakes, William J. Hoskins, Stephen C. Rubin, Wanda K. Jones, Lois Almadrones, (unknown), Douglass Chapman, Patricia E. Saigo	68
18	A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma 1988 ·Investigational New Drugs ·Paul B. Chapman, Jonathan E. Kolitz, Thomas B. Hakes, Janice Gabrilove, Karl Welte, V J Merluzzi, (unknown), Edward C. Bradley, Michael Konrad, Roland Mertelsmann	23
19	Nonpharmacologic factors in the development of posttreatment nausea with adjuvant chemotherapy for breast cancer 1988 ·Cancer ·Paul B. Jacobsen, (unknown), Jimmie C. Holland, Michael A. Andrykowski, William H. Redd, Thomas B. Hakes, Richard J. Kaufman, Violante E. Currie	69
20	Primary chemotherapy and the role of second-look laparotomy in non-dysgerminomatous germ cell malignancies of the ovary 1988 ·Gynecologic Oncology ·Charles H. Pippitt, Joanna M. Cain, Thomas B. Hakes, Virginia K. Pierce, John L. Lewis	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact